IC-MPGN
Clinical trials for IC-MPGN explained in plain language.
Never miss a new study
Get alerted when new IC-MPGN trials appear
Sign up with your email to follow new studies for IC-MPGN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to halt rare kidney disease progression
Disease control Recruiting nowThis study is testing whether an oral medication called iptacopan can help people with a rare kidney disease called idiopathic immune-complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). About 106 adults and adolescents will take either iptacopan or a placebo pill…
Matched conditions: IC-MPGN
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug trial targets rare kidney diseases
Disease control Recruiting nowThis study is testing an experimental drug called ADX-038 for people with specific immune-related kidney diseases. Researchers will enroll 45 adults with conditions like IgA nephropathy or C3 glomerulopathy to see if the drug is safe and helps control their kidney disease. The go…
Matched conditions: IC-MPGN
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC